2023 ASSOCIATION HEALTH PLAN - EVIDENCE OF COVERAGE
FFECTIVE
ATE
ULY
AGE
OF
29.
Natural and herbal remedies that may be purchased without a prescription (over the
counter), through a web site, at a Physician or chiropractor’s office, or at a retail location
are excluded unless otherwise specified in this EOC and Your Schedule of Benefits.
30.
Aroma therapy, massage therapy, reiki therapy, thermograph, orthomolecular therapy,
contact reflex analysis, Bio-Energetic Synchronization Technique (B.E.S.T.), colonic
irrigation, magnetic innervation therapy and electromagnetic therapy are excluded.
31.
Charges related to the acquisition or use of marijuana are excluded, even if used for
medicinal purposes.
32.
Except as otherwise provided in the EOC, drugs, medicines, procedures, services, and
supplies to correct or enhance erectile function, enhance sensitivity, or to alter the shape
or appearance of a sex organ, or for sexual dysfunction (organic or inorganic),
inadequacy, or enhancement, including penile implants and prosthetics, injections, and
durable medical equipment are excluded.
33.
Any off-label use of growth hormone is excluded;
34.
Coverage for human growth hormone or equivalent is excluded unless specifically
covered and described within the EOC.
35.
Cryopreservation or storage charges for collection and storage of biologic materials,
including umbilical cord blood, for artificial reproduction or any other purpose are
excluded.
36.
Platelet rich plasma and stem cell related musculoskeletal injections are excluded.
37.
All experimental or investigational medical, surgical, or other health care procedures and
all transplants are excluded except as otherwise described within the EOC. We will
consider a procedure or treatment as experimental or investigational as follows:
a.
If outcome data from randomized controlled clinical trials, recommendations from
consensus panels, national medical associations, or other technology evaluation
bodies and from authoritative, peer-reviewed US medical or scientific literature:
i.
Is insufficient to show that the procedure or treatment is safe, effective, or
superior to existing therapy; or
ii.
Does not conclusively demonstrate that the service or therapy improves
the net health outcomes for total appropriate population for whom the
service might be rendered or proposed over the current diagnostic or
therapeutic interventions, even in the event that the service, drug,
biological, or treatment may be recognized as a treatment or service for
another condition, screening, or Illness;
b.
If the procedure or treatment has not been deemed consistent with accepted
medical practice by the National Institutes of Health, the Food and Drug
Administration, or Medicare;
c.
When the drug, biologic, device, product, equipment, procedure, treatment,
service, or supply cannot be legally marketed in the United States without the
final approval of the Food and Drug Administration or any other state or federal